Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | Updates from the ZUMA-8 trial: KTE-X19 for R/R CLL

Ian Flinn • 3 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Leukemia
ZUMA-8

Ian Flinn, MD, PhD, from Tennessee Oncology, Nashville, TN, discusses the ZUMA-8 trial (NCT03624036) looking at KTE-X19 for R/R chronic lymphocytic leukemia (CLL). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Ian Flinn

SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
2:18
SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
Ian Flinn • 9 Dec 2021
Unanswered questions in frontline CLL treatment
0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
Umbralisib and ublituximab in patients with CLL and comorbidities
1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
Debulking strategies in CLL before venetoclax therapy
2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Ian Flinn • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Ian Flinn • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Ian Flinn • 6 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Ian Flinn • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals